← Back to home

ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN-IGG ASSOCIATED DISORDERS (MOGAD)

Clinical trials for ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN-IGG ASSOCIATED DISORDERS (MOGAD) explained in plain language.

Never miss a new study

Get alerted when new ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN-IGG ASSOCIATED DISORDERS (MOGAD) trials appear

Sign up with your email to follow new studies for ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN-IGG ASSOCIATED DISORDERS (MOGAD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

CAR-T therapy targets autoimmune diseases, but trial never started

Disease control Terminated

This study planned to test a new CAR-T cell therapy called LCAR-AIO in adults with relapsed or treatment-resistant neurological autoimmune diseases, including multiple sclerosis and myasthenia gravis. The goal was to check safety and find the right dose. However, the trial was wi…

Matched conditions: ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN-IGG ASSOCIATED DISORDERS (MOGAD)

Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control

Last updated Jun 27, 2026 14:02 UTC

ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN-IGG ASSOCIATED DISORDERS (MOGAD)

Get alerted when new ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN-IGG ASSOCIATED DISORDERS (MOGAD) trials appear

CAR-T therapy targets autoimmune diseases, but trial never started